12:00 AM
 | 
Jun 03, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AP26113: Interim Phase I/II data

Interim data from 44 refractory patients with ALK-positive or EFGR-positive NSCLC in the dose-escalation Phase I portion of an open-label, U.S. Phase I/II trial showed that once-daily oral AP26113 led to DLTs of grade 3 elevated aspartate aminotransferase (ALT) levels at the 240 mg dose and grade 4 dyspnea at the 300 mg dose. Ariad said that <300 mg doses "are being explored further." The Phase I portion is evaluating single ascending-doses of 30-300 mg AP26113. Of 18 evaluable ALK-positive patients, AP26113 produced 10 responses. Of 12 evaluable EFGR-positive patients, AP26113 led to 1 response and 6 cases of stable disease. Ariad has not yet determined a...

Read the full 511 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >